抗菌新药Amadacycline的药理学研究进展  

Research progress of pharmacology of the new antimicrobial drugs Amadacycline

作　　者：刘军[1] 谢敬东[2] 

机构地区：[1]沈阳市第一人民医院药剂科,辽宁沈阳110044 [2]沈阳医学院,辽宁沈阳110034

出　　处：《中国医药导报》2011年第27期10-11,共2页China Medical Herald

摘　　要：Amadacycline(PTK-0796)是具有广谱作用的第三代四环素类抗生素,其对多重耐药以及敏感的革兰阳性菌、革兰阴性菌、厌氧菌以及非典型病原体都有着很好的抗菌活性。与万古霉素、利奈唑胺等抗感染药物相比,A-madacycline有着很好的体内药效。对于皮肤及皮肤组织感染的患者,Amadacycline有着很好的疗效及安全性,未发生严重的不良反应事件,也未出现过不良反应导致停止用药的现象。总之,Amadacycline将会成为未来抗菌药物的"明星"。Amadacycline（PTK-0796） is third-generation tetracycline antibiotics with broad-spectrum,which has good antibacterial activity toward multi-drug resistant and sensitive Gram-positive bacteria,Gram-negative bacteria,anaerobes and atypical pathogens.Compared with anti-infective drugs,such as Vancomycin and Linezolid,Amadacycline has good efficacy in vivo.For patients with skin and skin tissue infection,Amadacycline has good efficacy and safety.No serious adverse events or drug discontinuance caused by adverse reactions occur.In total,Amadacycline will be the star of future antimicrobial drugs.

关 键 词：Amadacycline 四环素 耐甲氧西林金黄色葡萄球菌 复杂皮肤及皮肤组织感染 

分 类 号：R978.14[医药卫生—药品]